Artiva Biotherapeutics, Inc. (NasdaqGM: ARTV)
Health Care · Biotechnology · US
$11.72
-0.42% today · +317.4% 1Y
Artiva Biotherapeutics, Inc. (NasdaqGM: ARTV) operates in the Biotechnology industry within the Health Care sector. The company is valued at $575.44M and employs 115 people.
Over the last twelve months the share price has gained 317.4%, trading between 2.22 and 14.53.
Tweenvest scores Artiva Biotherapeutics, Inc. across four factors: quality 29/100. Its strongest factor is quality.
ARTV price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $575.44M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.21
- Dividend yield
- —
- Beta (5Y)
- 2.18
- 52-week high
- $14.53
- 52-week low
- $2.22
- Avg volume (3M)
- —
- Shares outstanding
- 48.89M
- Employees
- 115
- Next earnings
- —
About Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
- ISIN
- US04317A1079
- Founded
- 2019
- Listed since
- Jul 19, 2024
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.26 | -1.70% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $439.02 | -0.73% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $147.48 | -0.87% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $547.02 | -1.05% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $825.08 | -1.02% |
| argenx SEENXTBR: ARGX | $64.17B | €895.40 | +1.84% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $150.71 | -5.11% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.